Vital Therapies Receives a Hold from BTIG

By Carrie Williams

BTIG analyst Sean Lavin reiterated a Hold rating on Vital Therapies (NASDAQ: VTL) on March 7. The company’s shares closed yesterday at $4.25, close to its 52-week low of $3.85.

According to TipRanks.com, Lavin is a 5-star analyst with an average return of 10.3% and a 60.1% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Trivascular Technologies, and Obalon Therapeutics Inc.

Vital Therapies has an analyst consensus of Moderate Buy.

Based on Vital Therapies’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $0 and GAAP net loss of $11.73 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $9.86 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Vital Therapies, Inc. engages as a biotherapeutic company, which develops a cell-based system for the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal. The company was founded in May 23, 2003 and is headquartered in San Diego, CA.